Prothena Corporation plc PRTA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -11.31%
- 1 year
- -19.18%
- Open
- 8.79
- Prev close
- 8.88
- Mkt cap
- 434.82M
- Vol
- 452.30K
- Avg vol
- 472.70K
- EPS
- -0.82
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.35
- High
- 8.90
- Forward P/E
- -3.57
- Beta
- 0.16
- Short ratio
- 17.35
- Inst. own
- 96.97%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 15.72
- 200-d avg
- 20.26
- 1y target
- 49.75
Key statistics
- Market cap
- 824.89M
- Enterprise value
- 311.20M
- Trailing P/E
- 0.00
- Forward P/E
- -3.57
- PEG ratio
- 0.00
- Price / sales
- 6.19
- Price / book
- 1.54
- EPS (TTM)
- -2.46
- Beta
- 0.16
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -98.86%
- Revenue (TTM)
- 133.35M
- Revenue growth
- -98.90%
- Free cash flow
- -63.20M
- Total cash
- 519.26M
- Total debt
- 11.49M
- Return on equity
- -22.90%
- Shares outstanding
- 53.81M
- Short % of float
- 23.59%
- 50-day average
- 15.72
- 200-day average
- 20.26
Analyst view
Consensus: buy
- Target (low)
- 22.00
- Target (mean)
- 49.75
- Target (high)
- 94.00
- Strong buy3
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -1.04.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -1.18 | -1.10 | +0.08 | +6.78% |
| Aug 8, 2024 | Jun 1, 2024 | -1.01 | 1.22 | +2.23 | +220.79% |
| May 8, 2024 | Mar 1, 2024 | -1.21 | -1.34 | -0.13 | -10.74% |
| Feb 15, 2024 | Dec 1, 2023 | -1.23 | -1.26 | -0.03 | -2.44% |
| Nov 2, 2023 | Sep 1, 2023 | -0.26 | 0.38 | +0.64 | +246.15% |
| Aug 3, 2023 | Jun 1, 2023 | -0.92 | -1.03 | -0.11 | -11.96% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 20, 2024 | Chardan Capital | init | — | Buy |
| Dec 19, 2024 | B of A Securities | main | Neutral | Neutral |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 1, 2024 | B of A Securities | main | Neutral | Neutral |
| Oct 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- Website
- prothena.com
News
- Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares of Company Stock
- Prothena (NASDAQ:PRTA) Major Shareholder William Scully Buys 100,000 Shares of Stock
- Prothena (NASDAQ:PRTA) Shares Break Below Two Hundred Day Moving Average – What’s Next?
- Prothena's Partnership Strategy: Growth Driver or Limitation?
- Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Price Target of $24.57
- Prothena (NASDAQ:PRTA) Stock: Insider William Scully Acquires 125,000 Shares
- CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
- 4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day
- Prothena Corporation plc (NASDAQ:PRTA) Receives $24.57 Consensus PT from Analysts
- Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Your note
Sign in to keep a note on PRTA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COOKE SHANE M | Director | Conversion of Exercise of derivative security | Jan 9, 2023 | 0 |
| GARREN HIDEKI | Officer | Conversion of Exercise of derivative security | Sep 12, 2023 | 0 |
| KARP CAROL D | Officer | Conversion of Exercise of derivative security | Oct 3, 2023 | 0 |
| KINNEY GENE G PH.D. | Chief Executive Officer | Conversion of Exercise of derivative security | May 16, 2023 | 12,793 |
| MALECEK MICHAEL J. | Officer | Conversion of Exercise of derivative security | Sep 26, 2023 | 0 |
| NGUYEN TRAN BRYAN | Chief Financial Officer | Conversion of Exercise of derivative security | May 16, 2023 | 3,200 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 21.53% | 11,584,280 | 177.59M | Sep 29, 2024 |
| FMR, LLC | 14.99% | 8,066,983 | 123.67M | Sep 29, 2024 |
| Wellington Management Group, LLP | 7.77% | 4,178,788 | 64.06M | Sep 29, 2024 |
| Blackrock Inc. | 7.49% | 4,028,387 | 61.76M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 7.10% | 3,822,434 | 58.60M | Sep 29, 2024 |
| Palo Alto Investors Lp | 3.23% | 1,737,964 | 26.64M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Specialized-Health Care Fund | 5.59% | 3,007,603 | 46.11M | Jul 30, 2024 |
| Fidelity Growth Company Fund | 4.38% | 2,355,277 | 36.11M | Oct 30, 2024 |
| Price (T.Rowe) New Horizons Fund | 3.52% | 1,891,627 | 29.00M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.02% | 1,086,121 | 16.65M | Oct 30, 2024 |
| Fidelity Growth Company K6 Fund | 1.52% | 816,390 | 12.52M | Oct 30, 2024 |
| Fidelity Series Growth Company Fund | 1.41% | 758,605 | 11.63M | Oct 30, 2024 |